Results 121 to 130 of about 4,765,367 (286)

iSPARC 2020 Annual Report to the Massachusetts Department of Mental Health

, 2020
In Fiscal Year 2020 (FY20), iSPARC continued to leverage DMH’s investment to rapidly translate findings from mental health services and implementation research into best practices for individuals with lived experience, their families, and the providers ...
Implementation Science and Practice Advances Research Center
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Developing a national strategy to support implementation of reablement for community-dwelling people living with dementia

Implementation Science Communications
Background Dementia reablement is globally recommended to support people living with dementia to maximise their independence. Despite this, dementia reablement is not broadly available and there is currently no consensus around how it should be ...
Claire MC O’Connor, Sasha Houlden, Christopher J Poulos, Michele Callisaya, Angela Collins, Kylie Miskovski, Glenys Petrie, John Quinn, Natalie Taylor, Susan Kurrle, Kaarin J. Anstey   +10 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Explaining site-level fidelity within a national initiative to implement a VA patient safety guidebook: the difference-making role of networks & communications

Implementation Science Communications
Background Implementation fidelity—the degree to which an intervention is executed as intended—is critical for evaluating healthcare interventions' success.
Jennifer L. Sullivan, Edward J. Miech, Marlena H. Shin, Jeffrey A. Chan, Michael Shwartz, Ann Borzecki, Hassen Abdulkerim, Edward Yackel, Sachin Yende, Amy K. Rosen   +9 more
doaj   +1 more source

A Full-Cycle Analysis of the EPIS Framework: Exploration, Preparation, Implementation, Sustainment

Xiehe Yixue Zazhi
Implementation science aims to facilitate the efficient dissemination and sustainable application of evidence based interventions, and has accordingly generated a variety of theories, models, and frameworks.
HUANG Zizhen, XU Dong, ZHONG Dongmei, NING Zhiqing, ZHU Junlin, LI Qingqing, HUANG Wanqing, Kera Swanson, Gregory A. Aarons   +8 more
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

What are the determinants leading to innovation in manufacturing firms [PDF]

, 2013
In this paper, a comprehensive model of innovation determinants is analyzed based on empirical data gathered from 184 manufacturing firms located in the Northern Marmara region in Turkey.
Ulusoy, Gündüz, Günday, Gürhan, Alpkan, Lütfihak, Kılıç, Kemal   +3 more
core   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source